OCT a good AMD screening tool

Article

Optical coherence tomography (OCT) is an effective screening tool for wet age-related macular degeneration (AMD).

Optical coherence tomography (OCT) is an effective screening tool for wet age-related macular degeneration (AMD), according to the results of a study published in the May issue of the British Journal of Ophthalmology.

James Talks and colleagues from the Royal Victoria Infirmary, Newcastle Upon Tyne, UK, carried out a retrospective audit of a consecutive series of 134 new patients referred with suspected wet AMD. If visual acuity (VA) was 6/60, an OCT was performed and if the OCT was consistent with wet AMD, the patient underwent simultaneous fundus fluorescein angiography (FFA) and indocyanine green angiography (ICGA). The number of additional diagnoses made using ICGA were recorded.

Twenty-three (17.16%) of the 134 patients had OCT only and were not found to have wet AMD. FFA and ICGA were performed in 111 patients, with 90 patients (81%) showing wet AMD.

OCT had a sensitivity, in this clinic, of 1 and a specificity of 0.65 for detecting wet AMD. ICGA provided additional diagnoses in 19 (14.17%) patients and detected specific vascular abnormalities in 58% of the occult lesions.

Although ICGA can provide an additional diagnosis it does not define vascular abnormalities in all occult cases. OCT, however, has proved to be an effective method of screening wet AMD.

Recent Videos
Patrick C. Staropoli, MD, discusses clinical characterisation of Hexokinase 1 (HK1) mutations causing autosomal dominant pericentral retinitis pigmentosa
Richard B. Rosen, MD, discusses his ASRS presentation on illuminating subclinical sickle cell activities using dynamic OCT angiography
ASRS 2024: Socioeconomic barriers and visual outcomes in patients with rhegmatogenous retinal detachments, from Sally S. Ong, MD
Ashkan Abbey, MD, speaks about his presentation on the the CALM registry study, the 36-month outcomes of real world patients receiving fluocinolone acetonide 0.18 mg at the annual ASRS meeting in Stockholm, Sweden.
Nikoloz Labauri, MD, FVRS, speaks at the 2024 ASRS meeting about suspensory macular buckling as a novel technique for addressing myopic traction maculopathy
Jordana Fein, MD, MS, speaks with Modern Retina about the IOP outcomes with aflibercept 8 mg and 2 mg in patients with DME through week 48 of the phase 2/3 PHOTON trial at the annual ASRS meeting in Stockholm, Sweden.
John T. Thompson, MD, discusses his presentation at ASRS, Long-Term Results of Macular Hole Surgery With Long-Acting Gas Tamponade and Internal Limiting Membrane Peeling
ASRS 2024: Michael Singer, MD, shares 100-week results from the RESTORE trial
© 2024 MJH Life Sciences

All rights reserved.